F. Barbut and J. Petit, Epidemiology of Clostridium difficile-associated infections, Clinical Microbiology and Infection, vol.7, issue.8, 2001.
DOI : 10.1046/j.1198-743x.2001.00289.x
URL : https://doi.org/10.1046/j.1198-743x.2001.00289.x

L. Mcdonald, Burden of Clostridium difficile infection in the United States, 2015.

A. Ananthakrishnan, Clostridium difficile infection: epidemiology, risk factors and management, Nature Reviews Gastroenterology & Hepatology, vol.14, issue.1, pp.17-26, 2011.
DOI : 10.1093/clinids/22.5.813

B. Smyth, P. Rooney, I. Poxton, and D. Monnet, Update of Clostridium difficile infection due 286 to PCR ribotype 027 in Europe, Euro Surveill, vol.13, issue.5, 2008.

O. Group, Fidaxomicin versus vancomycin for Clostridium difficile infection, 2011.

J. Peltier, P. Courtin, E. Meouche, I. Lemee, L. Chapot-chartier et al., Clostridium 301, 2011.

J. Mainardi, The peptidoglycan of stationary-phase Mycobacterium tuberculosis 305 predominantly contains cross-links generated by L,D-transpeptidation, J Bacteriol, vol.190, issue.307, pp.4360-306, 2008.

J. Mainardi, J. Hugonnet, F. Rusconi, M. Fourgeaud, L. Dubost et al., Unexpected inhibition of peptidoglycan LD- 326 transpeptidase from Enterococcus faecium by the beta-lactam imipenem, J Biol Chem, vol.327, issue.328, pp.30414-30422, 2007.

J. Mainardi, R. Villet, T. Bugg, C. Mayer, and M. Arthur, Evolution of peptidoglycan 347 biosynthesis under the selective pressure of antibiotics in Gram-positive bacteria, FEMS, vol.348, 2008.

J. Brouard and M. Arthur, Synthesis of mosaic peptidoglycan cross-bridges by hybrid 351 peptidoglycan assembly pathways in gram-positive bacteria, J Biol Chem, vol.279, issue.352, pp.41546-41556, 2004.

G. Auger, J. Van-heijenoort, D. Mengin-lecreulx, and D. Blanot, A MurG assay which utilises a synthetic analogue of lipid I, FEMS Microbiology Letters, vol.219, issue.1, pp.115-119, 2003.
DOI : 10.1016/S0378-1097(02)01203-X